(Rye Brook, NY, October 10, 2018) –The Leukemia & Lymphoma Society (LLS) continues to lead cutting-edge research to advance treatments for myeloma and lymphoma. Adding to the momentum, the organization today announced a $1,175,000 commitment by the Schwartz Ward Family Foundation (SWFF) of Chicago to support two unique research initiatives including a novel therapy for a rare form of lymphoma and an innovative ...
RULE COULD RESULT IN COMPREHENSIVE COVERAGE FOR PATIENTS BECOMING UNAFFORDABLE; LEAVE MANY UNCOVERED Patient groups representing millions of Americans with serious health conditions filed an amicus curiae (or friend-of-the-court) brief today in the U.S. District Court case, Association for Community Affiliated Plans v. United States, explaining the devastating impact patients could face under the fi...
Washington, D.C. (September 26, 2018) – The Leukemia & Lymphoma Society (LLS) commends the U.S. House of Representatives for approving a funding package today that will provide much-needed additional resources for federal cancer research efforts. The U.S. Senate passed this funding agreement with strong bipartisan support last week. The legislation now heads to the White House to be signed into law. “...
Rye Brook, NY, (September 25,2018) - As The Leukemia & Lymphoma Society’s (LLS) Light The Night fundraising campaign continues to beat growth records, leading national companies and brands are signing on to help light the path to cancer cures and give hope to cancer patients nationwide. Light The Night brings light to the darkness of cancer through 140 inspirational evening walks across the US and Canada each f...
RYE BROOK, NY, September 12, 2018 – For 16 years, Burlington Stores has partnered with The Leukemia & Lymphoma Society (LLS), funding research and lifesaving treatments. Together, they have saved lives and helped bring smiles to those touched by blood cancers, with more than $32 million raised to date. However, with nearly 1.3 million people in the U.S. living with or in remission from blood cancers, there is s...
View full release here. Rye Brook, NY (August 28, 2018) – Contributing to nearly every advance in blood cancer research and treatment in decades, The Leukemia & Lymphoma Society (LLS) has invested more than $1.2 billion in cancer research, with groundbreaking results in immunotherapy, genomics and personalized medicine that are improving and saving lives of patients. These revolutionary new t...
View multimedia release here. Rye Brook, N.Y. (Aug. 7, 2018) — As costs for cancer care skyrocket – projected to be $173 billion by 2020, a 39 percent increase from 2010 – The Leukemia & Lymphoma Society® (LLS) is renewing its call for action to ease the cost of cancer care for patients. Today, LLS released a national “Progress Report on the Cost of Cancer Care,” a review of policy measures tak...
Rye Brook, N.Y. (July 20, 2018) – Progress in treating acute myeloid leukemia (AML), a blood cancer that takes more than 10,000 lives in the United States each year, took an important step forward today with the U.S. Food & Drug Administration (FDA) approval of ivosidenib (Tibsovo®) for patients who have a specific genetic mutation called IDH1. The Leukemia & Lymphoma Society (LLS), a leader i...
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: